# A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

> **NCT01096043** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 69 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Placebo
- **DRUG:** Strata 1 CXL-1020
- **DRUG:** Strata 2 CXL-1020
- **DRUG:** Strata 3 CXL-1020

## Key facts

- **NCT ID:** NCT01096043
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2016-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096043, "A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01096043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*